Sanofi said it would halt development of its vaccine against Covid-19 based on mRNA technology despite it having showed positive early-stage trial results.
The French pharma company is also working on another coronavirus jab, in partnership with GlaxoSmithKline, based on a more traditional manufacturing technique, which it aims to bring to market by the end of the year if regulators approve.
“There is no public health need for an another messenger RNA vaccine” against Covid-19, Thomas Triomphe, the company’s head of vaccines, told AFP.
您已閱讀38%（541字），剩餘62%（900字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。